Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation

Imagem de Miniatura
Arquivos
art_FANELLI_Effects_of_losartan_in_monotherapy_or_in_association_2011.PDF (1.26 MB)
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER PHYSIOLOGICAL SOC
Autores
Citação
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, v.301, n.3, p.F580-F587, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Fanelli C, Fernandes BH, Machado FG, Okabe C, Malheiros DM, Fujihara CK, Zatz R. Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation. Am J Physiol Renal Physiol 301: F580-F587, 2011. First published June 8, 2011; doi:10.1152/ajprenal.00042.2011.-We recently standardized a model (L(Lact)) of severe chronic kidney disease based on impaired nephrogenesis by suppression of angiotensin II activity during lactation (Machado FG, Poppi EP, Fanelli C, Malheiros DM, Zatz R, Fujihara CK. Am J Physiol Renal Physiol 294: F1345-F1353, 2008). In this new study of the L(Lact) model, we sought to gain further insight into renal injury mechanisms associated with this model and to verify whether the renoprotection obtained with the association of the angiotensin II receptor blocker losartan (L) and hydrochlorothiazide (H), which arrested renal injury in the remnant kidney model, would provide similar renoprotection. Twenty Munich-Wistar dams, each nursing six pups, were divided into control, untreated, and L(Lact) groups, given losartan (L; 250 mg.kg(-1).day(-1)) until weaning. The male LLact offspring remained untreated until 7 mo of age, when renal functional and structural parameters were studied in 17 of them, used as pretreatment control (L(Lact)Pre), and followed no further. The remaining rats were then divided among groups L(Lact) + V, untreated; L(Lact) + L, given L (50 mg.kg(-1).day(-1)) now as a therapy; L(Lact) + H, given H (6 mg.kg(-1).day(-1)); and L(Lact) + LH, given L and H. All parameters were reassessed 3 mo later in these groups and in age-matched controls. At this time, L(Lact) rats exhibited hypertension, severe albuminuria, glomerular damage, marked interstitial expansion/inflammation, enhanced cell proliferation, myofibroblast infiltration, and creatinine retention. L monotherapy normalized albuminuria and prevented hypertension and the progression of renal injury, inflammation, and myofibroblast infiltration. In contrast to the remnant model, the LH combination promoted only slight additional renoprotection, perhaps because of a limited tendency to retain sodium in L(Lact) rats.
Palavras-chave
angiotensin II, AT(1) receptor, thiazides, chronic kidney disease
URI
https://observatorio.fm.usp.br/handle/OPI/22610
Referências
  1. Fujihara CK, 2007, AM J PHYSIOL-RENAL, V292, pF1810, DOI 10.1152/ajprenal.00521.2006
  2. Haas CS, 2004, CONNECT TISSUE RES, V45, P73, DOI 10.1080/03008200490442644
  3. Pohl M, 2010, J BIOL CHEM, V285, P41935, DOI 10.1074/jbc.M110.150284
  4. WALLENSTEIN S, 1980, CIRC RES, V47, P1
  5. Oroszlan M, 2010, TRANSPL IMMUNOL, V23, P125, DOI 10.1016/j.trim.2010.05.003
  6. Eddy AA, 2000, PEDIATR NEPHROL, V15, P290
  7. Vogt L, 2008, J AM SOC NEPHROL, V19, P999, DOI 10.1681/ASN.2007060693
  8. Garcia-Estan J, 2006, CLIN SCI, V110, P227, DOI 10.1042/CS20050165
  9. Kang DH, 2001, J AM SOC NEPHROL, V12, P1448
  10. Abbate M, 2006, J AM SOC NEPHROL, V17, P2974, DOI 10.1681/ASN.2006040377
  11. JEPSEN FL, 1979, VIRCHOWS ARCH A, V383, P265, DOI 10.1007/BF00430245
  12. KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186
  13. Fine LG, 2008, KIDNEY INT, V74, P867, DOI 10.1038/ki.2008.350
  14. TUFROMCREDDIE A, 1995, AM J PHYSIOL-RENAL, V269, pF110
  15. Nangaku M, 2006, J AM SOC NEPHROL, V17, P17, DOI 10.1681/ASN.2005070757
  16. Heyman SN, 2008, AM J NEPHROL, V28, P998, DOI 10.1159/000146075
  17. Gonzalez-Villalobos R, 2005, AM J PHYSIOL-RENAL, V288, pF420, DOI 10.1152/ajprenal.00243.2004
  18. Guron G, 1997, HYPERTENSION, V29, P91
  19. Kliem V, 1996, KIDNEY INT, V49, P666, DOI 10.1038/ki.1996.95
  20. Kriz W, 1998, NEPHROL DIAL TRANSPL, V13, P2781, DOI 10.1093/ndt/13.11.2781
  21. Lasaitiene D, 2004, AM J PHYSIOL-RENAL, V286, pF1144, DOI 10.1152/ajprenal.00236.2003
  22. Machado FG, 2008, AM J PHYSIOL-RENAL, V294, pF1345, DOI 10.1152/ajprenal.00020.2008
  23. Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2
  24. Miyazaki Y, 1998, J CLIN INVEST, V102, P1489, DOI 10.1172/JCI4401
  25. Noronha IL, 2002, NEPHROL DIAL TRANSPL, V17, P363, DOI 10.1093/ndt/17.3.363
  26. Rodriguez-Iturbe B, 2010, NEPHRON CLIN PRACT, V116, pC81, DOI 10.1159/000314656
  27. Tanaka T, 2010, CURR OPIN NEPHROL HY, V19, P43, DOI 10.1097/MNH.0b013e3283328eed
  28. Wu L L, 1997, Kidney Int Suppl, V63, pS221

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/16